A Better Fit for Hard-to-Heal Wounds

Chronic wounds rarely present in neat, predictable shapes. Pressure ulcers can tunnel beneath intact skin, diabetic wounds may extend into irregular cavities and fragile peri-wound tissue can make placement more difficult. For buyers, the ability of a product to conform to the wound is therefore more than a matter of handling. It needs to reach the surfaces requiring treatment without clinicians having to work around the limitations of its form.

Persistent bacterial burden can make these wounds even harder to manage, while repeated antibiotic exposure brings limitations of its own. When evaluating a technology, buyers need to understand how it manages the local wound environment while also supporting tissue repair. The two cannot be considered in isolation. The physical form of the product plays a role here as well. Sheet-based products can be difficult to position against deep or irregular surfaces, especially when a wound includes tunneling or sinus tracts.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

The evidence behind the product also needs to reflect the patients likely to receive it. Chronic wound populations are often clinically complex, and older adults may have multiple comorbidities and lengthy treatment histories. Research drawn from narrowly defined populations may therefore tell buyers less about how a product will perform in difficult wounds. It is important to look at evidence involving relevant patients and wound types while also recognizing the difference between prospective real-world evidence and randomized controlled trial data.

That evidence has implications for reimbursement as well. Even a promising technology can have limited practical reach when coverage requirements prevent routine use across payer populations. The depth of supporting research becomes particularly important as a product moves beyond Medicare-focused use toward wider private coverage, where expectations for randomized trial evidence may be more demanding.

“Omeza Complete Matrix’s malleable, water-free format is designed to conform to irregular wound beds, including tunnels and sinus cavities, while cold-water fish peptides provide a scaffold for tissue growth.”

How the product works in day-to-day care matters alongside its biological mechanism. Refrigeration and specialized storage can make use more difficult in home care and outpatient clinics. The application also needs to remain manageable for clinicians outside major wound centers, particularly when material has to reach crevices or be placed around fragile tissue at the wound edge. Surgical use introduces additional sterility requirements, bringing packaging and handling into the purchasing decision. Buyers also need to consider whether the product can move from one care setting to another without requiring different storage procedures or additional preparation.

The source of the material can influence whether patients and care settings are comfortable using it. Products derived from human or animal tissue may raise religious or patient-preference concerns in some settings. Marine-derived materials avoid several of those issues, although sourcing controls and sterility testing still need to be examined. Natural inputs also make manufacturing consistency important because the materials require repeated quality checks before release. Their natural origin does not lessen the need for disciplined process control.

Omeza addresses these requirements with Omeza Complete Matrix, or OCM, an FDA-cleared drug-device wound matrix made from marine-derived components. Its malleable, water-free format is designed to conform to irregular wound beds, including tunnels and sinus cavities, while cold-water fish peptides provide a scaffold for tissue growth. The formulation also contains pharmaceuticalgrade marine lipids intended to support inflammation control and wound repair. OCM comes in single-use vials, requires no refrigeration and can be applied across both the wound bed and peri-wound area. For organizations evaluating regenerative wound-healing technology, its wound conformity, straightforward handling, clinical evidence and ongoing randomized trials provide a practical combination of features to consider.